Article
Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.
Cancer discovery - 1 Mar 2016
Girotti Maria Romina, Gremel Gabriela, Lee Rebecca, Galvani Elena, Rothwell Dominic, Viros Amaya, Mandal Amit Kumar, Lim Kok Haw Jonathan, Saturno Grazia, Furney Simon J, Baenke Franziska, Pedersen Malin, Rogan Jane, Swan Jacqueline, Smith Matthew, Fusi Alberto, Oudit Deemesh, Dhomen Nathalie, Brady Ged, Lorigan Paul, Dive Caroline, Marais Richard
Abstract excerpt
UNLABELLED: Targeted therapies and immunotherapies have transformed melanoma care, extending median survival from ∼9 to over 25 months, but nevertheless most patients still die of their disease. The aim of precision medicine is to tailor care for individual patients and improve outcomes. To this end, we developed protocols to facilitate individualized treatment decisions for patients with advanced melanoma,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.